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StatinsHypertension is associated with heightened cardiac sympathetic drive whilst statins reduce angiotensin II
(ATII) signalling, superoxide anion production and increase nitric oxide bioavailability, events that can
potentially reduce peripheral cardiac sympathetic neurotransmission. We therefore investigated whether
pravastatin alters peripheral cardiac sympathetic control in the spontaneously hypertensive rat (SHR). SHRs
(16–18 weeks) had signiﬁcantly (pb0.05) enhanced atrial 3H-norepinephrine (3H-NE) release to ﬁeld
stimulation compared to normotensive WKYs. 2-week pravastatin supplementation signiﬁcantly reduced 3H-
NE release to levels observed in the WKY. In-vivo, pravastatin lowered resting heart rate (HR) in the SHR
despite not affecting arterial blood pressure or serum cholesterol. In SHR atria/right stellate ganglion
preparations, the HR response to stellate stimulation (1, 3, and 5 Hz) was also signiﬁcantly reduced by
pravastatin whilst the HR response to exogenous NE (0.025–5 μmol) remained similar. The nitric oxide
synthase (NOS) inhibitor L-NAME (1 mmol/l) increased 3H-NE release by similar amounts in atria from
supplemented and non-supplemented SHRs, whilst Western blotting showed no difference in protein levels
of nNOS, eNOS, guanylyl cyclase, or the NADPH oxidase subunits Gp91 and P40phox. Pravastatin signiﬁcantly
reduced cardiac ATII levels and angiotensin converting enzyme 1 and 2 expressions whilst protein levels of
the ATII receptor (ATR1) remained unchanged in the SHR. Immunohistochemistry co-localised ATR1 with
tyrosine hydroxylase positive neurons in the stellate ganglion. The ATR1 antagonist Losartan (5 μmol)
equalised release of 3H-NE to comparable levels in supplemented and non-supplemented SHRs. These results
suggest 2-week pravastatin treatment reduces cardiac ATII, and prevents its facilitatory effect on NE release
thus normalising cardiac sympathetic hyper-responsiveness in SHRs.rring),
NC-ND license.© 2010 Elsevier Ltd.Open access under CC BY-NC-ND license.1. Introduction
HMG-CoA reductase inhibitors have been shown to have many
pleiotropic actions in addition to those arising directly from lowering
plasma cholesterol. These include inhibition of Rho isoprenylation
thereby stabilising eNOS mRNA [1], activation of protein kinase
Akt [2] increasing nitric oxide bioavailability, and inhibition of
geranylgeranyl dependent modiﬁcation of Rac1 to reduce agonist-
mediated activation of NADPH oxidase/superoxide anion production
[3]. They can also downregulate the ATII type 1 receptor (ATR1)
expression in a Rho A dependent manner (see [4] and [5] for reviews).
These actions can produce overlapping effects to improve vascular
endothelial function in a cholesterol independent manner. Moreover,
meta-analyses suggest that statins may have antihypertensive effects
in patients with elevated arterial blood pressure regardless of plasma
cholesterol levels (e.g. [6]).Hypertension is also associated with dysfunction of the autonomic
nervous system in both humans and animal models. Moreover, this
neural phenotype has been implicated in the aetiology and progres-
sion of the disease [7]. We have previously shown that a signiﬁcant
component of the cardiac sympatho-vagal dysfunction in the
spontaneously hypertensive rat (SHR) arises pre-synaptically at the
cardiac end organ level secondary to impaired neuronal nitric oxide
synthase signalling [8,9]. Adenoviral vector gene transfer of nNOS can
restore vagal acetylcholine release and reduce norepinephrine (NE)
release to levels seen in control WKY rats [8–10]. It can also decrease
post-synaptic excitability to β adrenergic agonists by decreasing the
L-type calcium current [11]. Normalisation of NE release can also be
achieved by feeding animals with L-arginine to increase peripheral
sympathetic NO production [12].
Conversely, oxidative stress is able to augment peripheral sympa-
thetic responsiveness of heart rate by reducing the expression of
nNOS [13]. Angiotensin II (ATII) has been shown to facilitate NE release
via the ATR1 in the WKY [14]. Reducing oxidative stress and ATII
signalling, and increasing NO bioavailability may therefore represent
ways by which statin treatment could potentially rectify peripheral
cardiac sympathetic hyperactivity associated with hypertension.
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could reduce cardiac sympathetic neurotransmission and heart rate
responsiveness to local sympathetic nerve stimulation in the adult
SHR with established hypertension via a nitric oxide, oxidative stress
and/or ATII dependent mechanisms.
2. Methods
2.1. Animals
Sixteen-week-old male SHRs (n=73) and Wistar Kyoto (WKY,
n=40) rats (Harlan, UK) were kept under standard laboratory
conditions with free access to water and rat chow for 2 weeks. A
subgroup of the SHRs (n=41) and WKYs (n=20) had their drinking
water supplemented with pravastatin (100 mg/l). Experiments con-
formed to the Guide for the Care and Use of Laboratory Animals
published by the US National Institutes of Health (NIH Publication No.
85-23, revised 1996) and the Animals (Scientiﬁc Procedures) Act 1986
(UK). Experiments were performed under British Home Ofﬁce Project
License PPL 30/2130 and PPL 30/2630.
2.2. Heart rate and blood pressure measurements
In a subgroup of rats (n=24 SHRs and n=16 WKYs), heart rate
and arterial blood pressure were measured via a 3F portex catheter in
the left carotid artery whilst anaesthetised with 1–3% isoﬂurane and
100% oxygen prior to in-vitro experimentation as described previously
[12].
2.3. Serum cholesterol levels
Rats were euthanised with an intraperitoneal injection of pento-
barbitone and blood samples taken via intraventricular puncture
before the heart and thoraxwere removed. Atrial tissuewas harvested
to characterise sympathetic function in terms of 3H-NE release and
heart rate changes whilst ventricular tissue was used for Western
blotting and ATII level measurements. Atrial tissue underwent
various pharmacological treatments including the addition of ATR1
antagonists, ATII itself and NOS inhibition that would confound
measurements of these proteins in this tissue type, which is why it
was not used for molecular analysis.
Blood samples from intraventricular puncture were immediately
spun at 5000 rpm for 10 min. Red blood cells and serum (in EDTA
tubes) were separated and samples frozen in liquid nitrogen before
being stored at −80 °C. Serum lipid analyses were undertaken by
the Clinical Biochemistry Department at the John Radcliffe Hospital,
Oxford, using the Siemens ADVIA 2400 automated chemistry analyzer
(Siemens Healthcare Diagnostics Ltd, Frimley, UK) with a cholesterol
oxidase method.
2.4. 3H-Norepinephrine release to ﬁeld stimulation from right atrial
preparations
The spontaneously beating right atrium was isolated and trans-
ferred to a preheated (37±0.2 °C), continuously oxygenated, water-
jacketed organ bath containing 3 ml Tyrode solutionwhere the atrium
was pinned ﬂat on a silver stimulating electrode. The method for
determining the local release of 3H-NE to ﬁeld stimulation 5 Hz (15 V,
1 ms pulse width, for 1 min) was identical to that which we have
previously described [12].
2.5. Isolated sinoatrial node/right stellate ganglion preparation
The spontaneously beating atria with intact sympathetic inner-
vation were isolated and transferred to a preheated (37±0.2 °C),
continuously oxygenated, water-jacketed organ bath containing 100-ml Tyrode solution. The method for dissecting and measuring
responses to sympathetic nerve stimulation (SNS) has been described
previously [13]. Before starting each protocol, the mounted atria were
allowed to equilibrate for 80 min until beating rate stabilised
(±5 beats per minute, bpm, over 20 min). The Tyrode's solution in
the organ bath was replaced approximately every 30 min throughout
each protocol. The stellate was stimulated at 1, 3, 5 and 7 Hz, (20 V,
1 ms pulse duration for 30 s). Drugs were applied directly to the organ
bath and incubated until a consistent response to sympathetic nerve
stimulation (SNS) was obtained.
2.6. Western blotting
Protein was extracted and Western blotting performed as
described previously in detail [12]. The following primary antibodies
were used: nNOS (Santa Cruz); eNOS (Transduction Laboratory); sGC
(Sigma); Gp91 (Santa Cruz); P40phox (Santa Cruz), ACE1 (Abcam),
ACE2 (Abcam) and ATR1 (Santa Cruz). The ﬁlm was digitised and the
relative band densities were determined using UN-SCAN-IT, gel
6.1, software according to manufacturer's instructions. Protein band
densities were normalised to β-actin (Abcam) band densities that
served as a protein loading control.
2.7. Myocardial ATII levels
ATII levels were also measured using an enzyme immunoassay
(SPI Bio, #A05880) according to manufacturer's instructions. Results
were standardised as pg ATII per mg of extracted protein.
2.8. Immunohistochemistry
Immunohistochemistry was performed as previously described
[15] with the following modiﬁcations. Right stellate ganglia were
dissected free and ﬁxed in 10% formalin at 4 °C. Prior to processing,
samples were transferred to a solution containing 30% sucrose and 1%
formalin in PBS for 24 hours. Tissue was permeabilised and blocked in
0.3% Triton X100 and 1% bovine serum albumin for one hour. Tyrosine
hydroxylase (TH, mouse) primary antibody (Sigma, 1:200) and
biotinylated horse anti-mouse (Santa Cruz, 1:200) secondary antibody
were used, which were further labeled with streptavidin Texas red. To
assess TH/ATR1 co-localisation, the preparation was blocked using a
streptavidin kit, and then incubated with ATR1 primary antibody
(Santa Cruz, 1:200) and biotinylated secondary antibody and then
labeledwith streptavidin ﬂuoroscein. Tissuewas scanned and digitally
photographed at ×20 magniﬁcation using a Nikon Eclipse TE2000-U
inversion ﬂuorescent light microscope and appropriate ﬁlters.
2.9. Solutions and drugs
The Tyrode solution contained (mmol/l) NaCl 120, KCl 4.7, MgSO4
1.2, NaHCO3 25, CaCl2 2, KH2PO4 1.2 and glucose 11, and was aerated
with 95% O2/5% CO2 (pH 7.4). Its temperature was continuously
monitored (Digitron 1408-K gauge) and kept at 37±0.2 °C.
The effects of SNS were compared to cumulative doses of bath
applied NE (0.1–5 μmol, Sigma) in a darkened room to determine if
the actions of pravastatin treatment were pre or post-synaptic.
Losartan (5 μmol, LKT Laboratories) was used as a speciﬁc ATR1
antagonist. The effects of ATII (20 nmol/l, Sigma) on 3H-NE release
were also evaluated. L-NAME (1 mmol/l, Sigma) was used as a non-
speciﬁc inhibitor of both endothelial and neuronal nitric oxide
synthase.
2.10. Statistical analysis
Data are presented as mean±S.E.M. One-way repeated measures
ANOVA followed by Tukey's post hoc analysis was used to evaluate
Table 1
Characteristics of pravastatin supplemented and non-supplemented SHRs and WKYs.
SHR non-supplemented
(n=32)
SHR Pravastatin supplemented
(n=41)
WKY non-supplemented
(n=20)
WKY Pravastatin supplemented
(n=20)
Pravastatin intake (mg/kg) 0 9.42±0.15 (n=25) 0 10.00±0.20* (n=12)
Serum cholesterol (mmol/l) 1.0±0.1 (n=7) 1.1±0.3 (n=7) 2.1±0.1** (n=7) 1.6±0.1* (n=7)
Ventricular weight/body weight (×10−3) 3.23±0.03* (n=15) 3.27±0.04* (n=25) 2.94±0.03 (n=12) 2.88±0.04 (n=12)
Mean ABP (mmHg) 173±4* (n=11) 172±4* (n=13) 86±3 (n=8) 83±4 (n=8)
Heart rate in-vivo (bpm) 353±11** (n=11) 340±9* (n=16) 287±5 (n=8) 281±12 (n=8)
Heart rate in-vitro (bpm) 231±10 (n=19) 241±7 (n=16) 252±14 (n=8) 258±6*** (n=8)
*SHR vs. WKY pb0.05. **SHR vs. WKY and pravastatin supplemented vs. non-supplemented pb0.05. ***SHR vs. WKY pravastatin supplemented only pb0.05.
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more than 2 groups, between groups ANOVA was used to compare
the means with post-hoc Tukey's HSD test to assess individual
signiﬁcance. An unpaired Student's t-test assuming unequal variances
and sample sizes was used to evaluate the effect of an intervention
between experimental groups of different sizes. Statistical signiﬁ-
cance was accepted at Pb0.05 and was not affected by analysing
the data in terms of absolute beats per minute (bpm) or percentage
changes in heart rate or pulse interval.3. Results
3.1. Animal characteristics
The phenotypical characteristics of both pravastatin supplemented
and non-supplemented SHRs and age matched, normotensive WKYs
are summarised in Table 1. Two-week pravastatin supplementation
did not alter serum cholesterol levels in the SHR. However, the same
treatment regime did lower serum cholesterol in WKY rats, although
the WKYs had far higher baseline cholesterol levels and a slightly
higher voluntary daily intake of pravastatin. As expected, ventricular
weight/body weight ratios, an indication of left ventricular hypertro-
phy, were signiﬁcantly higher in the SHR compared to the WKY as
was mean arterial blood pressure, but neither of these variables were200 
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Fig. 1. (A) Representative raw data traces and (B) group mean data showing signiﬁcantly r
treated SHRs (in red, n=8) compared to non-supplemented SHRs (black, n=9). (C) Raw d
cumulative doses of norepinephrine (0.025–5 μmol) between pravastatin supplemented (rsigniﬁcantly altered by 2-week pravastatin supplementation in either
SHR or WKY rats.
A signiﬁcant reduction in heart ratemeasured in-vivowas observed
in the SHR group in the resting state following pravastatin treatment
although no difference in heart rate was seen after equilibration
of isolated atria in the organ bath in-vitro, consistent with the notion
that pravastatin altered resting cardiac autonomic tone via a pre-
synaptic mechanism. However pravastatin supplementation did not
lower resting heart rate in the SHR to the levels observed in theWKYs.3.2. Pravastatin normalised peripheral cardiac sympathetic hyperactivity
by reducing norepinephrine release to levels seen in the WKY
In the SHR the heart rate response to SNS in-vitrowas signiﬁcantly
larger than that of theWKY. In addition it was signiﬁcantly reduced by
pravastatin treatment at 1–5 Hz (pravastatin supplemented n=8 vs.
non-supplemented n=9) as can be seen in Fig. 1, whilst the response
to bath applied NE remained unchanged (pravastatin supplemented
n=8 vs. non-supplemented n=8). The heart rate response to SNS or
bath applied NEwas not signiﬁcantly altered by pravastatin treatment
in the WKY (pravastatin supplemented n=8 vs. non-supplemented
n=8) as can be seen in Fig. 2. This suggests that pravastatin reduces
peripheral cardiac sympathetic control of heart rate via a pre-synaptic
mechanism in the SHR only.200 
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Fig. 2. (A) Representative raw data traces and (B) group mean data showing no difference in the heart rate response to sympathetic nerve stimulation in pravastatin treated WKYs
(in red, n=8) compared to non-supplemented WKYs (black, n=8). (C) Raw data trace and (D) group mean data showing no difference in the heart rate response to cumulative
doses of norepinephrine (0.025–5 μmol) between pravastatin supplemented (red, n=8) and non-supplemented WKYs (black, n=8).
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stimulation compared to the WKY, indicating that a signiﬁcant
component of sympathetic hyper-responsiveness occurs at the end
organ level. The release of 3H-NE to ﬁeld stimulation was signiﬁcantly
reduced by pravastatin treatment in the SHR to levels observed in
WKY atria (see Fig. 3, non-supplemented SHRs n=22 vs. pravastatin
supplemented SHRs n=12). Pravastatin treatment had no effect
on 3H-NE release in the normotensive WKY rats however (non-
supplemented WKYs n=12 vs. pravastatin supplemented WKYs
n=12) consistent with the in-vivo and in-vitro recorded heart rate
data.
3.3. Increased nitric oxide signaling or reduced oxidative stress was not
solely responsible for the action of pravastatin on peripheral cardiac
sympathetic hyperactivity
The pleiotropic effects of statins include increasing nitric oxide
production and decreasing oxidative stress. We therefore measured0
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Fig. 3. Group mean data showing a signiﬁcantly (*pb0.05) higher release of 3H-
norepinephrine (3H-NE) in response to ﬁeld stimulation (5 Hz) in non-supplemented
SHRs (n=22) compared to non-supplemented WKYs (n=12). Whilst pravastatin
treatment has no signiﬁcant effect on 3H-NE release in WKYs (n=12) it signiﬁcantly
reduces release in the SHR (n=12) to WKY levels.the effect of a non-speciﬁc inhibitor of nitric oxide synthase (L-
NAME) on 3H-NE release during ﬁeld stimulation in pravastatin
supplemented (n=6) and non-supplemented (n=6) SHRs. As can
be seen in Fig. 4C, L-NAME produced a signiﬁcant increase in 3H-NE
release in both groups although the signiﬁcant difference between
pravastatin supplemented and non-supplemented SHRs remained,
suggesting that the nitric oxide pathway is not the predominant
route pravastatin acts on to reduce 3H-NE release. Protein levels of
nNOS (pravastatin supplemented n=6 vs. non-supplemented n=6),
eNOS (pravastatin supplemented n=6 vs. non-supplemented n=6)
and sGC (pravastatin supplemented n=6 vs. non-supplemented
n=6) normalised to β-actin as a loading control, were also similar
between the two groups (Fig. 4A and B). We also measured protein
levels of the NADPH oxidase subunits P40phox (pravastatin
supplemented n=6 vs. non-supplemented n=6), and Gp91 (pra-
vastatin supplemented n=6 vs. non-supplemented n=6), which
were also similar between the two groups (Fig. 4A and B).
3.4. The effect of Pravastatin on ATII mediated control of norepinephrine
release
As can be seen in Fig. 5A, the ATR1 antagonist losartan signiﬁcantly
reduced the release of 3H-NE during ﬁeld stimulation in non-
supplemented SHRs (n=5) to levels observed in pravastatin supple-
mented SHRswhilst having little effect in the latter group (n=5). This
suggests that pravastatin acted to reduce angiotensin II augmentation
of NE release in the SHR. Conversely exogenous ATII was able to
signiﬁcantly increase 3H-NE release during ﬁeld stimulation in both
groups of SHRs (non-supplemented SHRs, n=6 vs. pravastatin
supplemented SHRs, n=8), an effect abolished by losartan. Losartan
was also able to abolish the facilitatory action of ATII on the increase in
3H-NE release during ﬁeld stimulation in the WKY (n=6, data not
shown), as has been shown by others previously [14].
Using immunohistochemistry we demonstrated that the ATR1
is co-localised with tyrosine hydroylase containing sympathetic
neurons innervating the heart (see Fig. 6A). Levels of cardiac ATII
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Fig. 5. The angiotensin II type 1 (ATII) receptor inhibitor losartan (5 μmol) signiﬁcantly
(*pb0.05) reduces the release of 3H-norepinephrine (3H-NE) in response to ﬁeld
stimulation (5 Hz) in non-supplemented SHRs (n=5) to the same levels observed in
SHRs treated with pravastatin (n=5) (A). Exogenous ATII (20 nmol/l) is able to
signiﬁcantly increase 3H-NE release (*pb0.05) in both non-supplemented (n=6) and
pravastatin treated (n=8) SHRs, an effect that can be reversed by losartan (B).
Fig. 4. Representative Western blots (A) and group mean data (B) showing no
difference in the expression of neuronal or endothelial nitric oxide synthase (nNOS,
eNOS), soluble guanylyl cyclase (sGC) or the NADPH oxidase subunits P40Phox and
Gp91 in myocardial tissue from pravastatin treated (n=6) and non-supplemented
(n=6) SHRs. Western blot band optical density was normalised to that of β-actin as
a loading control. Although pravastatin supplemented SHRs have signiﬁcantly lower
3H-norepinephrine (3H-NE) release in response to ﬁeld stimulation (5 Hz) compared
to non-supplemented SHRs (+pb0.05), the non-speciﬁc NOS inhibitor L-NAME
(1 mmol/l) signiﬁcantly (*pb0.05) increases the release of 3H-NE by similar amounts
in both pravastatin treated (n=6) and non-supplemented (n=6) groups (C) and does
not normalise the difference between the two groups.
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supplemented SHRs, n=7 vs. pravastatin supplemented SHRs, n=7,
Fig. 6B) although plasma ATII levels were not signiﬁcantly reduced
(non-supplemented SHRs, 52±6 pg/ml, n=7 vs. pravastatin supple-
mented SHRs, 45±4 pg/ml, n=7). No changes were observed in the
levels of myocardial ATR1 expression between non-supplemented
(n=6) and pravastatin supplemented (n=6) SHRs measured by
Western blotting. However a signiﬁcant reduction in ACE 1 and
2 protein levels were observed (non-supplemented n=6, and
pravastatin supplemented SHRs n=6, in each group) which could
account for the lower myocardial ATII levels (Fig. 6C).
4. Discussion
The main new ﬁndings of this study are as follows.First, pravastatin supplementation for 2 weeks did not signiﬁcantly
alter mean arterial blood pressure or serum cholesterol in the adult
SHR with established hypertension, but signiﬁcantly reduced resting
heart rate in-vivo, although not to the levels observed in the WKY.
Exaggerated release of cardiac NE in response to ﬁeld stimulation in
the SHR compared to the WKY in-vitro was normalised (to levels
observed in the WKY) by pravastatin treatment. In the SHR this also
translated into a reduction in the heart rate response to peripheral
cardiac sympathetic nerve stimulation whilst the response to
exogenous NE remained unchanged, suggesting the actions of
pravastatin were mediated pre-synaptically. Secondly, the reduction
in cardiac sympathetic hyperactivity by pravastatin in the SHR cannot
be reversed by NOS inhibition. Treatment with pravastatin also did
not alter the expression of nNOS, eNOS, sGC or the NADPH oxidase
subunits Gp91 or P40phox, suggesting free radical signalling systems
are not involved in this neuronal phenotype. Finally, the action
of pravastatin in the SHR was completely reversed by the ATR1
antagonist losartan. This was associated with signiﬁcantly lower
levels of cardiac ATII as well as ACE 1 and 2 following treatment with
pravastatin, supporting a role for the cardiac angiotensin II system in
modulating NE release.
4.1. Pravastatin normalises cardiac sympathetic hyperactivity in the SHR
Sympathetic hyperactivity in the SHR is well documented both
centrally [16,17] and at the level of the end organ [8–10]. Others have
Fig. 6. (A) Immunohistochemistry showing tyrosine hydroxylase (TH) staining with
Texas red in a neuron of the right stellate ganglia also staining positive for the
angiotensin II type 1 receptor (ATR1) in green (ﬂuroscein) (×20 magniﬁcation). Co-
localisation is demonstrated by overlap of staining in yellow. (B) Myocardial
angiotensin II (ATII) levels are signiﬁcantly (*pb0.05) reduced following pravastatin
treatment (n=7) compared to non-supplemented SHRs (n=7). (C) Representative
Western blots and group mean data showing a signiﬁcant (*pb0.05) reduction in
myocardial angiotensin converting enzyme (ACE) 1 and 2 expression from pravastatin
treated (n=6) and non-supplemented (n=6) SHRs, with no signiﬁcant change ATR1
protein expression (n=6 in each group). Western blot band optical density was
normalised to that of β-actin as a loading control.
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have suggested that a centrally mediated mechanism may be at least
partly responsible for this. Four-week treatment with high dose
atorvastatin (50 mg/kg/day) lowered urinary catecholamines [18]
and was associated with increased eNOS expression and reduced
oxidative stress in the rostral ventrolateral medulla of the SHR [19], an
effect mimicked by eNOS adenoviral vector transfection to this area
[20]. Similar sympatholytic actions of statins have been observed in apacing induced heart failure model in the rabbit. Here simvastatin
treatment normalised muscle sympathetic nerve activity, baroreﬂex
function and plasma catecholamines [21,22] and improved left
ventricular systolic function [23]. This was associated with down-
regulation of ATR1, NADPH oxidase subunits and reduced NADPH
oxidase activity in the rostral ventrolateral medulla [23,24]. Our study
is the ﬁrst to show normalisation of peripheral cardiac sympathetic
hyperactivity in terms of NE release following treatment with
pravastatin, establishing that a signiﬁcant component of the neuronal
dysfunction resides at the end organ level.
The fact that there was no change in serum cholesterol levels
suggests that the effects on sympathetic hyperactivity we observe are
independent from inhibition of HMG Co-A reductase. We observed
that the same treatment regime did lower serum cholesterol levels in
WKY rats, although theWKY had far higher baseline cholesterol levels
than the SHR, which is consistent with other reports (e.g. [25]). Others
also observe no change in serum cholesterol in the SHR with both
longer durations of treatment and higher doses of pravastatin (e.g.
5 mg/kg for 8 weeks [26], 20 mg/kg/day for 4 weeks [27] or 50 mg/kg/
day for 6 weeks [28]). The 9–10 mg/kg/day dose used in this study
may appear high when directly compared to the 40–80 mg/day
pravastatin dose usually prescribed in humans. However, it is well
known that rats metabolise statins to a greater extent than humans,
and the dose used in this study is at the lower end of the ranges
used in previous studies in the SHR model, which have varied from
5 mg/kg/day [26] to 50 mg/kg/day [28].
We observed a signiﬁcant reduction in resting heart rate in-vivo
following pravastatin treatment, although there was no difference in
baseline intrinsic beating rate of the sinoatrial node preparation in-vitro
supporting a pre-synaptic reduction in sympathetic neurotransmission.
Given the larger differences in the heart rate response to stellate
stimulation we observe in-vitro, it is likely that heart rate during daily
activity in-vivo may be reduced by an even greater degree by statin
treatment although this was not directly measured. We observed no
fall in mean arterial blood pressure or reduction in left ventricular
hypertrophy (heartweight/bodyweight ratio) in the SHR. Other studies
using longer treatment protocols in younger rats before the hyperten-
sive phenotype clearly manifests have observed antihypertensive
effects in both anaesthetised and telemetered SHRs. For example, 4-
week treatment with 20 mg/kg/day pravastatin lowers blood pressure,
reduces left ventricular hypertrophy and improves vascular function via
increased NO bioavailability and reduced oxidative stress in 8-week-old
SHRs [27]. Eight-week treatment with 5 mg/kg/day in similarly aged
SHRs also reduces blood pressure, left ventricular hypertrophy and
susceptibility to arrhythmias [26]. We used a short 2-week treatment
protocol in 16–18 week old SHRs with established hypertension.
Whether a longer treatment protocol in this age group of SHR would
produce a reversal of the hypertensive phentotype and reduce left
ventricular hypertrophy remains to be determined.
4.2. Mechanism of action of Pravastatin on cardiac sympathetic
hyperactivity
The pleiotropic actions of statins on oxidative stress, NO bio-
availability and ATR1 expression have been well characterised (see [4]
and [5] for reviews). Here we observe no change in NO dependent
modulation of sympathetic neurotransmission following treatment
with pravastatin in the SHR, and no change in the expression of either
eNOS, nNOS or sGC protein whilst expression of NADPH oxidase
subunits Gp91 and P40phox also remains unchanged. We demon-
strated that inhibition of ATR1 with losartan equalised the release
of 3H-NE between control and pravastatin treated SHRs. We found
no signiﬁcant change in cardiac ATR1 protein following pravastatin
treatment, although other groups have found that statins reduced
ATR1 expression in the brain [19]. However, we clearly demonstrate
that pravastatin lowers cardiac ATII levels as well as expression of
105N. Herring et al. / Journal of Molecular and Cellular Cardiology 50 (2011) 99–106ACE 1 and 2 providing a mechanism for our observation. A reduction
in overall cardiac ACE activity by statin treatment in conditions asso-
ciated with left ventricular hypertrophy has been reported previously
[29].
Interestingly plasma levels of ATII were not different between
pravastatin supplemented and non-supplemented SHRs. If longer
treatment protocols in this age group of SHR are able to lower plasma
ATII levels then this may very well contribute to an antihypertensive
effect in addition to the peripheral cardiac sympatholytic action of the
drug. The ATR1 is also known to be up-regulated with hypercholes-
terolaemia [30], whereas the SHR has low overall cholesterol levels.
This may be relevant to human hypertensive patients who also
have hypercholesterolaemia where statins may have more of an
antihypertensive and sympatholytic effect. Meta-analyses of the small
trials using statins in hypertensive patients however suggest that
the antihypertensive effects occur regardless of plasma cholesterol
levels [6].
The presence of post-synaptic ATR1 on cardiac myocytes including
sinoatrial node cells [31] is well documented. We directly demon-
strate the presence of ATR1 on tyrosine hydroxylase positive
sympathetic neurons innervating the heart. We also show that
exogenous ATII can increase evoked cardiac 3H-NE release and that
this can be blocked by the ATR1 antagonist losartan. The effect of ATII
on cardiac neurotransmission was ﬁrst demonstrated in the rabbit
[32], but has since been shown to occur via the ATR1 in the WKY rat
[14], and in human atria [33]. The mechanisms behind ATII dependent
facilitation of NE release is not completely understood but may
involve phospholipase C-diacylglycerol-protein kinase C dependent
effects on the exocytotic mechanism [34]. It is also possible that the
ATR1 indirectly couples to NOS or NOX-superoxide signalling (Fig. 7).
4.3. Perspectives
Sympathetic hyperactivity is found in both humans and animal
models of hypertension and has been implicated in both its aetiologyFig. 7. A diagram hypothesising the control of norepinephrine (NE) release from a cardiac
(nNOS) via stimulation of soluble guanylyl cyclase (cGC) and inhibition of N type calcium cur
modulated by oxidative stress. Conversely angiotensin II (ATII) stimulates NE release, althoug
receptor 1 (ATR1) levels remain unchanged. Two-week statin treatment does not alter neu
subunits Gp91 or P40phox.and progression. Statins can produce an antihypertensive action in
the SHR when initiated before the hypertensive phenotype
manifests itself, and this is associated with a reduction in the
activity of the sympathetic nervous system. Here we show that
statin treatment reduces peripheral cardiac sympathetic hyper-
activity even during established hypertension independent of
both serum cholesterol and any antihypertensive effect. We provide
evidence that this may occur via a reduction in local cardiac ATII
and ACE 1 and 2 levels, a pleiotropic effect of statins not previously
described, rather than via a nitric oxide or superoxide dependent
mechanism.
As well as being used as antihypertensive agents, statins may
also have anti-arrhythmic properties [24] since excessive cardiac
sympathetic drive can exacerbate pre-existing cardiac disease and
precipitate life-threatening ventricular arrhythmias. NE promotes
myocyte calcium inﬂux and increases the inotropic state of the heart,
thereby raising myocardial oxygen demand in the context of an
elevated heart rate and reduced diastolic coronary perfusion time.
Unsurprisingly indices of autonomic function suggest excessive
adrenergic drive is a poor prognostic indicator and can predict
mortality during many cardiovascular disease states [35,36] as well
as in asymptomatic individuals [37]. Targeting excessive cardiac
sympathetic drive directly, and combining this with indirect targeting
via the use of statins, is likely to be beneﬁcial.Funding
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